KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Interest Expenses (2017 - 2022)

Sarepta Therapeutics has reported Interest Expenses over the past 6 years, most recently at $6.7 million for Q4 2022.

  • Quarterly results put Interest Expenses at $6.7 million for Q4 2022, down 40.09% from a year ago — trailing twelve months through Sep 2023 was $6.7 million (down 87.07% YoY), and the annual figure for FY2023 was $22.0 million, down 58.67%.
  • Interest Expenses for Q4 2022 was $6.7 million at Sarepta Therapeutics, up from $6.3 million in the prior quarter.
  • Over the last five years, Interest Expenses for SRPT hit a ceiling of $25.7 million in Q4 2020 and a floor of $172000.0 in Q1 2019.
  • Median Interest Expenses over the past 5 years was $10.9 million (2018), compared with a mean of $11.8 million.
  • Biggest five-year swings in Interest Expenses: plummeted 97.75% in 2019 and later skyrocketed 7815.7% in 2020.
  • Sarepta Therapeutics' Interest Expenses stood at $7.2 million in 2018, then rose by 15.74% to $8.4 million in 2019, then soared by 206.85% to $25.7 million in 2020, then crashed by 56.64% to $11.2 million in 2021, then crashed by 40.09% to $6.7 million in 2022.
  • The last three reported values for Interest Expenses were $6.7 million (Q4 2022), $6.3 million (Q3 2022), and $17.0 million (Q2 2022) per Business Quant data.